A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder
dc.contributor.author | Haffajee, Rebecca L. | |
dc.contributor.author | Andraka-Christou, Barbara | |
dc.contributor.author | Attermann, Jeremy | |
dc.contributor.author | Cupito, Anna | |
dc.contributor.author | Buche, Jessica | |
dc.contributor.author | Beck, Angela J. | |
dc.date.accessioned | 2022-08-10T18:33:42Z | |
dc.date.available | 2022-08-10T18:33:42Z | |
dc.date.issued | 2020-09-14 | |
dc.identifier.citation | Substance Abuse Treatment, Prevention, and Policy. 2020 Sep 14;15(1):69 | |
dc.identifier.uri | https://doi.org/10.1186/s13011-020-00312-3 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/173830 | en |
dc.description.abstract | Abstract Background Evidence demonstrates that medications for treating opioid use disorder (MOUD) —namely buprenorphine, methadone, and extended-release naltrexone—are effective at treating opioid use disorder (OUD) and reducing associated harms. However, MOUDs are heavily underutilized, largely due to the under-supply of providers trained and willing to prescribe the medications. Methods To understand comparative beliefs about MOUD and barriers to MOUD, we conducted a mixed-methods study that involved focus group interviews and an online survey disseminated to a random group of licensed U.S. physicians, which oversampled physicians with a preexisting waiver to prescribe buprenorphine. Focus group results were analyzed using thematic analysis. Survey results were analyzed using descriptive and inferential statistical methods. Results Study findings suggest that physicians have higher perceptions of efficacy for methadone and buprenorphine than for extended-release naltrexone, including for patients with co-occurring mental health disorders. Insurance obstacles, such as prior authorization requirements, were the most commonly cited barrier to prescribing buprenorphine and extended-release naltrexone. Regulatory barriers, such as the training required to obtain a federal waiver to prescribe buprenorphine, were not considered significant barriers by many physicians to prescribing buprenorphine and naltrexone in office-based settings. Nor did physicians perceive diversion to be a prominent barrier to prescribing buprenorphine. In focus groups, physicians identified financial, logistical, and workforce barriers—such as a lack of addiction treatment specialists—as additional barriers to prescribing medications to treat OUD. Conclusions Additional education is needed for physicians regarding the comparative efficacy of different OUD medications. Governmental policies should mandate full insurance coverage of and prohibit prior authorization requirements for OUD medications. | |
dc.title | A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder | |
dc.type | Journal Article | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173830/1/13011_2020_Article_312.pdf | |
dc.identifier.doi | https://dx.doi.org/10.7302/5561 | |
dc.language.rfc3066 | en | |
dc.rights.holder | The Author(s) | |
dc.date.updated | 2022-08-10T18:33:42Z | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.